PRTC vs ROIV vs ATAI vs CMPS vs RXRX

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -11. 2% for Roivant Sciences Ltd. (ROIV). Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Roivant Sciences Ltd.

(ROIV) delivered a total return of +185. 4%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: ROIV returned +171. 9% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.

51β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 525% more volatile than PRTC relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 21% for Atai Beckley N. V — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -11. 2% for Roivant Sciences Ltd. (ROIV). On earnings-per-share growth, the picture is similar: Recursion Pharmaceuticals, Inc. grew EPS 14. 8% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, PRTC leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

COMPASS Pathways plc (CMPS) is the more profitable company, earning 0.

0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPS leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PureTech Health plc (PRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTC: -55. 9%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRTC is a small-cap quality compounder stock; ROIV is a mid-cap quality compounder stock; ATAI is a small-cap quality compounder stock; CMPS is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.